穿龙骨刺胶囊联合骨肽注射液治疗骨质增生症的疗效观察
|
摘要
目的探讨穿龙骨刺胶囊联合骨肽注射液治疗骨质增生的安全性和有效性。方法选取信阳市第一人民医院在2015年6月—2016年6月收治的骨质增生患者177例,随机分成对照组(88例)和治疗组(89例)。对照组患者肌肉注射骨肽注射液,2 mL/次,1次/d;治疗组患者在对照组的基础上餐前口服穿龙骨刺胶囊,6粒/次,3次/d。所有患者均治疗28 d。评价治疗后两组患者临床疗效,同时比较两组患者治疗前后两组临床症状积分、VAS评分和不良反应发生情况。结果治疗后,对照组和治疗组总有效率分别为79.55%、96.63%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者麻木、疼痛、肿胀以及屈展困难等骨质增生临床症状积分均显著降低(P<0.05);且治疗组骨质增生临床症状积分均显著低于对照组(P<0.05)。治疗后,两组患者VAS评分与治疗前相比显著降低(P<0.05);且治疗组VAS评分压痛指数明显低于对照组(P<0.05)。治疗期间,对照组患者不良反应的发生率为15.91%,显著高于治疗组患者的5.62%,两组比较差异具有统计学意义(P<0.05)。结论穿龙骨刺联合骨肽注射液治疗骨质增生临床疗效好,安全性高,具有一定的临床推广应用价值。
Objective To explore the safety and efficacy of Chuanlong Guci Capsules combined with Ossotide Injection in treatment of hyperostosis. Methods Patients(177 cases) with hyperostosis in the First People's Hospital of Xinyang City from June 2015 to June 2016 were randomly divided into control(88 cases) and treatment(89 cases) groups. Patients in the control group were im injected with Ossotide Injection on the basis of conventional treatment, 2 mL/time, once daily. Patients in the treatment group were po administered with Chuanlong Guci Capsules before meal on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 28 d. After treatment, clinical efficacy was evaluated, and clinical symptom score, VAS scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.55% and 96.63%, respectively, and there were differences between two groups(P < 0.05). After treatment, the clinical symptoms scores of numbness, pain, swelling, and difficulty in flexion and extension in two groups were significantly decreased(P < 0.05). And the clinical symptom scores of hyperostosis in treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the VAS scores in two groups were significantly decreased(P < 0.05). And the VAS scores in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the adverse reaction incidence in the control group was 15.91%, which was significantly higher than 5.62% in the treatment group, with significant difference between two groups(P < 0.05). Conclusion Chuanlong Guci Capsules combined with Ossotide Injection has good clinical efficacy in treatment of hyperostosis with high safety, which has a certain clinical application value.
Objective To explore the safety and efficacy of Chuanlong Guci Capsules combined with Ossotide Injection in treatment of hyperostosis. Methods Patients(177 cases) with hyperostosis in the First People's Hospital of Xinyang City from June 2015 to June 2016 were randomly divided into control(88 cases) and treatment(89 cases) groups. Patients in the control group were im injected with Ossotide Injection on the basis of conventional treatment, 2 mL/time, once daily. Patients in the treatment group were po administered with Chuanlong Guci Capsules before meal on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 28 d. After treatment, clinical efficacy was evaluated, and clinical symptom score, VAS scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.55% and 96.63%, respectively, and there were differences between two groups(P < 0.05). After treatment, the clinical symptoms scores of numbness, pain, swelling, and difficulty in flexion and extension in two groups were significantly decreased(P < 0.05). And the clinical symptom scores of hyperostosis in treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the VAS scores in two groups were significantly decreased(P < 0.05). And the VAS scores in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the adverse reaction incidence in the control group was 15.91%, which was significantly higher than 5.62% in the treatment group, with significant difference between two groups(P < 0.05). Conclusion Chuanlong Guci Capsules combined with Ossotide Injection has good clinical efficacy in treatment of hyperostosis with high safety, which has a certain clinical application value.
引文
[1]彭东,张红娜,陈杰.中医治疗骨质增生的现状[J].吉林医药学院学报,2011,32(1):44-47.
[2]孙立鹏,吕发明.中医药治疗骨质增生症的研究进展[J].新疆中医药,2015,33(2):62-65.
[3]马洁,宋燕青.骨肽注射液的临床应用及其药理作用[J].中国生化药物杂志,2016,36(2):16-18.
[4]施汀兰,冉长清.穿龙骨刺胶囊主要药效学实验研究[J].重庆中草药研究,2006,53(1):21-26.
[5]中华医学会骨科学分会.骨关节炎诊治指南(2007年版)[J].中华关节外科杂志:电子版,2007,1(4):287-291.
[6]Jensen M P,Chen C,Brugger A M.Interpretation of visual analog scale rating and change scores:a reanalysis of two clinical trials of postoperative pain[J].J Pain,2003,4(7):407-414.
[7]向太敏.骨质增生的中医治疗经验总结[J].亚太传统医药,2016,12(17):85-86.
[8]咎世永,高瑞华.中药联合物理疗法治疗膝关节骨质增生的临床疗效[J].中国医药指南,2015,13(8):214-215.
[9]施莱.骨肽注射液在骨科的应用进展[J].社区医学杂志,2010,8(7):38-39.
[10]阮链芝.骨肽注射液的临床应用[J].中国临床药学杂志,2008,17(5):320-322.
[11]杨进渝.穿龙骨刺胶囊治疗骨质增生症疗效观察[J].临床合理用药,2015,8(1A):25-26.
[12]张蓓.穿龙骨刺胶囊的研究[D].长春:吉林大学,2006.
[2]孙立鹏,吕发明.中医药治疗骨质增生症的研究进展[J].新疆中医药,2015,33(2):62-65.
[3]马洁,宋燕青.骨肽注射液的临床应用及其药理作用[J].中国生化药物杂志,2016,36(2):16-18.
[4]施汀兰,冉长清.穿龙骨刺胶囊主要药效学实验研究[J].重庆中草药研究,2006,53(1):21-26.
[5]中华医学会骨科学分会.骨关节炎诊治指南(2007年版)[J].中华关节外科杂志:电子版,2007,1(4):287-291.
[6]Jensen M P,Chen C,Brugger A M.Interpretation of visual analog scale rating and change scores:a reanalysis of two clinical trials of postoperative pain[J].J Pain,2003,4(7):407-414.
[7]向太敏.骨质增生的中医治疗经验总结[J].亚太传统医药,2016,12(17):85-86.
[8]咎世永,高瑞华.中药联合物理疗法治疗膝关节骨质增生的临床疗效[J].中国医药指南,2015,13(8):214-215.
[9]施莱.骨肽注射液在骨科的应用进展[J].社区医学杂志,2010,8(7):38-39.
[10]阮链芝.骨肽注射液的临床应用[J].中国临床药学杂志,2008,17(5):320-322.
[11]杨进渝.穿龙骨刺胶囊治疗骨质增生症疗效观察[J].临床合理用药,2015,8(1A):25-26.
[12]张蓓.穿龙骨刺胶囊的研究[D].长春:吉林大学,2006.